Novo Nordisk a Danish company headquartered in Copenhagen has particularly strong European market relationships and has invested in prescriber education programs across European diabetes specialist networks that sustain its market leadership position in its home region
Take nausea, for instance, the most commonly reported side effect of this medication
Clinical Studies 14.1 Weight Management Trials in Adults with Overweight or Obesity The safety and efficacy of SAXENDA for chronic weight management in conjunction with reduced caloric intake and increased physical activity were studied in three 56-week, randomized, double-blind, placebo-controlled trials
NICE recommends sleep hygiene measures and Cognitive Behavioural Therapy for Insomnia (CBT-I) as first-line treatments
Data are in line with results in randomised controlled trials and show the long-term stable benefit of once weekly semaglutide. Esther Walden, deputy head of care at Diabetes UK, said: This study suggests that improvements in blood sugars and weight loss can potentially be sustained in the longer term for adults with type 2 diabetes taking semaglutide as prescribed
